TYRA — Tyra Biosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1863127 ·
Last close
$19.57
Market Cap
$1.35B
52W High
$40.65
52W Low
$14.84
ADV30
610,723
Next earnings
2026-11-10
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -54,885,000 -51,122,000 727,526,000 456,016,000 34,682,000
Jun 2026 0 — -49,003,000 -45,558,000 383,362,000 73,835,000 29,698,000
Mar 2026 0 — -41,998,000 -39,305,000 412,040,000 84,955,000 24,465,000
Dec 2025 0 — -36,516,000 -33,834,000 282,609,000 77,387,000 23,432,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-119,482,000
Investing CF
$-33,092,000
Financing CF
$546,639,000
CapEx
$-301,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.64
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-507,243,000
Inventory
—
Receivables
—
ST Investments
$244,532,000
EBIT TTM
$-182,402,000
Pretax Income TTM
$-169,819,000
Interest Exp TTM
—
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -132,762,000 -119,947,000 282,609,000 23,432,000 259,177,000 -95,142,000
Dec 2024 0 -104,177,000 -86,481,000 363,558,000 20,407,000 343,151,000 -69,774,000
Dec 2023 0 -79,945,000 -69,134,000 225,857,000 21,595,000 204,262,000 -50,139,000
Dec 2022 0 -58,927,000 -55,325,000 266,181,000 8,352,000 257,829,000 -50,285,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-148,565,000
OpCashFlow TTM
—
Assets (Latest)
$383,362,000
Forward EPS
$-2.97

Peers — same industry

TickerNameMarket CapLastDaily %
ANAB ANAPTYSBIO, INC $1.36B $45.61 —
NUVB Nuvation Bio Inc. $1.37B $3.90 —
OCUL OCULAR THERAPEUTIX, INC $1.32B $6.02 —
NBTX Nanobiotix S.A. $1.39B $27.45 —
MNKD MANNKIND CORP $1.31B $4.07 —

News headlines (Yahoo Finance, 1h cache)

How Phase 2 Cancer Trial Data At Tyra Biosciences (TYRA) Has Changed Its Investment Story
2026-11-12 00:23 · Yahoo
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
2026-11-10 13:00 · Yahoo
Tyra Biosciences to Participate in Upcoming Investor Conferences
2026-11-05 21:05 · Yahoo
Tyra Biosciences (TYRA) Stock Looks Rich Against Its Book Value
2026-10-31 21:14 · Yahoo
Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value
2026-10-17 07:11 · Yahoo
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks
2026-10-14 12:35 · Yahoo
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2026-09-14 10:45 · Yahoo
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
2026-09-09 20:54 · Yahoo
Tyra disappoints investors with bladder cancer data
2026-09-09 15:46 · Yahoo
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
2026-09-09 14:44 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.